Most Downloaded

1
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for malignant lymphoma 2021 (English version)
Jun Zhu, Jun Ma, Union for China Lymphoma Investigators of Chinese Society of Clinical Oncology
2021, 33(3): 289-301. doi: 10.21147/j.issn.1000-9604.2021.03.01
[Abstract](12107) [FullText HTML](11076) [PDF 544KB](916)
2
Cervical cancer: Epidemiology, risk factors and screening
Shaokai Zhang, Huifang Xu, Luyao Zhang, Youlin Qiao
2020, 32(6): 720-728. doi: 10.21147/j.issn.1000-9604.2020.06.05
[Abstract](18199) [FullText HTML](27741) [PDF 194KB](535)
3
Cancer burden and trends in China: A review and comparison with Japan and South Korea
Dianqin Sun, Maomao Cao, He Li, Siyi He, Wanqing Chen
2020, 32(2): 129-139. doi: 10.21147/j.issn.1000-9604.2020.02.01
[Abstract](10963) [FullText HTML](12881) [PDF 1728KB](513)
4
Evaluation and reflection on claudin 18.2 targeting therapy in advanced gastric cancer
Jianwei Zhang, Ruilan Dong, Lin Shen
2020, 32(2): 263-270. doi: 10.21147/j.issn.1000-9604.2020.02.13
[Abstract](3222) [FullText HTML](7786) [PDF 181KB](485)
5
Cancer incidence and mortality in China, 2014
Wanqing Chen, Kexin Sun, Rongshou Zheng, Hongmei Zeng, Siwei Zhang, Changfa Xia, Zhixun Yang, He Li, Xiaonong Zou, Jie He
2018, 30(1): 1-12. doi: 10.21147/j.issn.1000-9604.2018.01.01
[Abstract](5864) [FullText HTML](3970) [PDF 1049KB](397)
6
Chinese guidelines for diagnosis and treatment of primary lung cancer 2018 (English version)
National Health Commission of the People’s Republic of China
2019, 31(1): 1-28. doi: 10.21147/j.issn.1000-9604.2019.01.01
[Abstract](89058) [FullText HTML](40886) [PDF 364KB](380)
7
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer 2018 (English version)
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for colorectal cancer working group
2019, 31(1): 117-134. doi: 10.21147/j.issn.1000-9604.2019.01.07
[Abstract](75962) [FullText HTML](41709) [PDF 325KB](364)
8
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer 2018 (English version)
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for persistent/recurrent and metastatic differentiated thyroid cancer working group
2019, 31(1): 99-116. doi: 10.21147/j.issn.1000-9604.2019.01.06
[Abstract](75373) [FullText HTML](39038) [PDF 826KB](316)
9
Chinese guidelines for diagnosis and treatment of esophageal carcinoma 2018 (English version)
National Health Commission of the People’s Republic of China
2019, 31(2): 223-258. doi: 10.21147/j.issn.1000-9604.2019.02.01
[Abstract](78247) [FullText HTML](40456) [PDF 3597KB](295)
10
Chinese guidelines for diagnosis and treatment of gastric cancer 2018 (English version)
National Health Commission of the People’s Republic of China
2019, 31(5): 707-737. doi: 10.21147/j.issn.1000-9604.2019.05.01
[Abstract](73600) [FullText HTML](39739) [PDF 1139KB](287)
11
Breast cancer: Epidemiology, risk factors and screening
Hangcheng Xu, Binghe Xu
2023, 35(6): 565-583. doi: 10.21147/j.issn.1000-9604.2023.06.02
[Abstract](4789) [FullText HTML](6691) [PDF 1063KB](272)
12
Incidence and mortality of thyroid cancer in China, 2008−2012
Lingbin Du, Runhua Li, Minghua Ge, Youqing Wang, Huizhang Li, Wanqing Chen, Jie He
2019, 31(1): 144-151. doi: 10.21147/j.issn.1000-9604.2019.01.09
[Abstract](3753) [FullText HTML](6605) [PDF 754KB](261)
13
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)
Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group
2019, 31(1): 84-98. doi: 10.21147/j.issn.1000-9604.2019.01.05
[Abstract](75456) [FullText HTML](39081) [PDF 323KB](256)
14
National guidelines for diagnosis and treatment of colorectal cancer 2020 in China (English version)
National Health Commission of the People’s Republic of China
2020, 32(4): 415-445. doi: 10.21147/j.issn.1000-9604.2020.04.01
[Abstract](11283) [FullText HTML](7568) [PDF 764KB](254)
15
Chinese guidelines for diagnosis and treatment of breast cancer 2018 (English version)
National Health Commission of the People’s Republic of China
2019, 31(2): 259-277. doi: 10.21147/j.issn.1000-9604.2019.02.02
[Abstract](75439) [FullText HTML](39466) [PDF 746KB](235)
16
Clinical features and outcomes of diffuse large B-cell lymphoma based on nodal or extranodal primary sites of origin: Analysis of 1,085 WHO classified cases in a single institution in China
Yuankai Shi, Ying Han, Jianliang Yang, Peng Liu, Xiaohui He, Changgong Zhang, Shengyu Zhou, Liqiang Zhou, Yan Qin, Yongwen Song, Yueping Liu, Shulian Wang, Jing Jin, Lin Gui, Yan Sun
2019, 31(1): 152-161. doi: 10.21147/j.issn.1000-9604.2019.01.10
[Abstract](3991) [FullText HTML](5620) [PDF 1111KB](229)
17
Integrating pathomics with radiomics and genomics for cancer prognosis: A brief review
Cheng Lu, Rakesh Shiradkar, Zaiyi Liu
2021, 33(5): 563-573. doi: 10.21147/j.issn.1000-9604.2021.05.03
[Abstract](3779) [FullText HTML](6468) [PDF 1109KB](221)
18
Evidence-based expert consensus on clinical management of safety of Bruton’s tyrosine kinase inhibitors (2024)
Zaiwei Song, Dan Jiang, Lingling Yu, Yixuan Chen, Daobin Zhou, Yue Li, Depei Wu, Lingli Zhang, Liyan Miao, Jun Ma, Jun Zhu, Hongmei Jing, Rongsheng Zhao, on behalf of the Steering Committee, the Consensus Panel and the Evidence Synthesis Group; Evidence-based Pharmacy Professional Committee of Chinese Pharmaceutical Association (CPA), Hospital Pharmacy Professional Committee of Chinese Pharmaceutical Association (CPA), Division of Therapeutic Drug Monitoring of Chinese Pharmacological Society (CPS), Expert Committee on Lymphoma of Chinese Society of Clinical Oncology (CSCO), Expert Committee on Leukemia of Chinese Society of Clinical Oncology (CSCO), Society of Integrative Cardio-Oncology of China Anti-Cancer Association (CACA), Chinese Society of Hematology of Chinese Medical Association (CMA), Hospital Pharmacy Professional Committee of Cross-Straits Medicine Exchange Association (SMEA)
2024, 36(3): 240-256. doi: 10.21147/j.issn.1000-9604.2024.03.02
[Abstract](3703) [FullText HTML](1829) [PDF 2997KB](217)
19
National guidelines for diagnosis and treatment of prostate cancer 2022 in China (English version)
National Health Commission of the People’s Republic of China
2022, 34(3): 270-288. doi: 10.21147/j.issn.1000-9604.2022.03.07
[Abstract](10339) [FullText HTML](4677) [PDF 991KB](200)
20
National guidelines for diagnosis and treatment of gastric cancer 2022 in China (English version)
National Health Commission of the People’s Republic of China
2022, 34(3): 207-237. doi: 10.21147/j.issn.1000-9604.2022.03.04
[Abstract](10614) [FullText HTML](5420) [PDF 3771KB](195)